Compare ALLR & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLR | ALUR |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 18.9M |
| IPO Year | N/A | N/A |
| Metric | ALLR | ALUR |
|---|---|---|
| Price | $1.00 | $1.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.50 | $9.25 |
| AVG Volume (30 Days) | ★ 148.6K | 113.3K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.02 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $1.02 |
| 52 Week High | $2.35 | $16.81 |
| Indicator | ALLR | ALUR |
|---|---|---|
| Relative Strength Index (RSI) | 37.75 | 41.88 |
| Support Level | $1.05 | $1.31 |
| Resistance Level | $1.18 | $1.71 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 8.93 | 29.45 |
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.